IHC - Oct-2 | Test | Sprint Diagnostic

No, fasting is not necessary for this test. It's performed on tissue samples, typically obtained through a biopsy or surgical procedure.

No specific preparation is needed. The tissue sample is usually collected by a healthcare provider during a biopsy or surgical procedure.

This test is typically ordered when a B-cell lymphoma is suspected, often following initial imaging studies or clinical examinations that suggest these conditions.

This test detects the presence or absence of the Oct-2 protein. It aids in distinguishing B-cell lymphomas from other types of lymphomas.

The frequency of this test depends on your doctor's advice and is usually performed during the diagnostic process or when monitoring the response to treatment.

The interpretation of the Oct-2 IHC test is based on the detection of the Oct-2 protein rather than a numerical value. A positive result indicates the presence of Oct-2, suggestive of B-cell lineage lymphomas.

As the test is performed on tissue samples, the main precautions involve the biopsy or surgical procedure used to obtain the sample.

Oct-2 levels can be influenced by the presence of B-cell lymphomas. There are no known modifiable factors that affect Oct-2 expression.

If your Oct-2 IHC test results are abnormal, you should consult a hematologist or an oncologist. They can provide guidance on the implications of the results and the subsequent steps to take.

While Oct-2 is primarily associated with B-cell lymphomas, its expression may be seen in other conditions. Therefore, the test result should be interpreted in conjunction with other clinical and diagnostic information.

Oct-2 is predominantly found in B-cells, a type of white blood cell. However, its detection is most commonly associated with B-cell lymphomas.

There are no specific medication restrictions before this test. However, you should always inform your doctor about any medications you're taking before any biopsy or surgical procedure.

No, this test requires a tissue sample usually obtained via a biopsy or surgical procedure. Therefore, it needs to be performed in a healthcare setting by a trained professional.

The Oct-2 IHC test is highly specific, but it should be interpreted in conjunction with other diagnostic tests and clinical findings for a comprehensive diagnosis.

In the fight against B-cell lymphomas and related conditions, the Oct-2 IHC test is a valuable diagnostic tool. It provides crucial information that can guide healthcare providers in the direction of the most effective treatment. Always remember, your healthcare team is there to provide support and guidance throughout your journey, ensuring that you receive the best care possible.